Long-term hepatitis B virus (HBV) response to Lamivudine-containing highly active antiretroviral therapy in HIV-HBV co-infected patients in Thailand

• Main Authors: Khamduang W., Gaudy-Graffin C., Ngo-Giang-Huong N., Jourdain G., Moreau A., Luekamlung N., Halue G., Buranawanitchakorn Y., Kunkongkapan S., Buranabanjasatean S., Lallemant M., Sirirungsi W., Goudeau A.
• Format: Article
• Language: English
• Published: 2014
• Online Access: http://www.scopus.com/inward/record.url?eid=2-s2.0-84864447642&partnerID=40&md5=2632dd8bd211cd6a59b788d3572a98b1; http://cmuir.cmu.ac.th/handle/6653943832/888
• Institution: Chiang Mai University

Background: Approximately 4 million of people are co-infected with HIV and Hepatitis B virus (HBV). In resource-limited settings, the majority of HIV-infected patients initiate first-line highly active antiretroviral therapy containing lamivudine (3TC-containing-HAART) and long-term virological resp...